ACADIA Pharmaceuticals 미래 성장
Future 기준 확인 4/6
ACADIA Pharmaceuticals (는) 각각 연간 26.6% 및 9.1% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 24.3% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 19.5% 로 예상됩니다.
주요 정보
26.6%
수익 성장률
24.3%
EPS 성장률
Biotechs 수익 성장 | 28.3% |
매출 성장률 | 9.1% |
향후 자기자본 수익률 | 19.5% |
애널리스트 커버리지 | Good |
마지막 업데이트 | 21 Nov 2024 |
최근 미래 성장 업데이트
ACADIA Pharmaceuticals Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions
Nov 08ACADIA Pharmaceuticals Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
Aug 09Recent updates
Acadia Pharmaceuticals: Proving The Naysayers Wrong
Nov 11ACADIA Pharmaceuticals Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions
Nov 08Acadia Pharmaceuticals: Nuplazid Performs In Q2 While Daybue Disappoints Again
Aug 26The Strong Earnings Posted By ACADIA Pharmaceuticals (NASDAQ:ACAD) Are A Good Indication Of The Strength Of The Business
Aug 14ACADIA Pharmaceuticals Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
Aug 09ACADIA Pharmaceuticals Inc.'s (NASDAQ:ACAD) Price Is Right But Growth Is Lacking
Aug 01Shareholders Will Probably Hold Off On Increasing ACADIA Pharmaceuticals Inc.'s (NASDAQ:ACAD) CEO Compensation For The Time Being
May 23ACADIA Pharmaceuticals Inc.'s (NASDAQ:ACAD) Price Is Right But Growth Is Lacking
Apr 24We're Interested To See How ACADIA Pharmaceuticals (NASDAQ:ACAD) Uses Its Cash Hoard To Grow
Mar 27Acadia Pharmaceuticals: Post Pimavanserin Study Setback Selloff May Continue
Mar 12ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Just Released Its Full-Year Earnings: Here's What Analysts Think
Mar 01Acadia Pharmaceuticals: New Daybue Drug Already Showing Signs Of Slowing
Feb 29Soleno Therapeutics And Acadia Pharmaceuticals: Hope For Prader-Willi Families
Jan 23ACADIA Pharmaceuticals Inc.'s (NASDAQ:ACAD) Share Price Boosted 35% But Its Business Prospects Need A Lift Too
Jan 03We're Interested To See How ACADIA Pharmaceuticals (NASDAQ:ACAD) Uses Its Cash Hoard To Grow
Dec 04Insufficient Growth At ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Hampers Share Price
May 22Acadia Pharmaceuticals: Nuplazid's (Pimavanserin) Last Hurrah
Oct 19FDA accepts Acadia's new drug application for Rett syndrome treatment trofinetide
Sep 12Acadia: Powerful Unfolding Catalysts
Aug 03Acadia Pharma submits marketing application to FDA for trofinetide to treat Rett syndrome
Jul 18수익 및 매출 성장 예측
날짜 | 수익 | 수익 | 잉여 현금 흐름 | 작전 현금 | 평균 애널리스트 수 |
---|---|---|---|---|---|
12/31/2026 | 1,150 | 205 | 203 | 268 | 15 |
12/31/2025 | 1,050 | 139 | 162 | 234 | 19 |
12/31/2024 | 978 | 123 | 157 | 255 | 20 |
9/30/2024 | 929 | 129 | 203 | 203 | N/A |
6/30/2024 | 891 | 31 | 80 | 81 | N/A |
3/31/2024 | 814 | -2 | 24 | 64 | N/A |
12/31/2023 | 726 | -61 | -23 | 17 | N/A |
9/30/2023 | 632 | -149 | -133 | -93 | N/A |
6/30/2023 | 551 | -111 | -74 | -34 | N/A |
3/31/2023 | 520 | -146 | -56 | -56 | N/A |
12/31/2022 | 517 | -216 | -114 | -114 | N/A |
9/30/2022 | 512 | -217 | -113 | -113 | N/A |
6/30/2022 | 512 | -205 | -130 | -130 | N/A |
3/31/2022 | 493 | -214 | -142 | -142 | N/A |
12/31/2021 | 484 | -168 | -127 | -126 | N/A |
9/30/2021 | 474 | -192 | -133 | -130 | N/A |
6/30/2021 | 463 | -262 | -141 | -136 | N/A |
3/31/2021 | 458 | -260 | -155 | -147 | N/A |
12/31/2020 | 442 | -282 | -144 | -136 | N/A |
9/30/2020 | 419 | -268 | -144 | -138 | N/A |
6/30/2020 | 393 | -225 | -139 | -134 | N/A |
3/31/2020 | 366 | -238 | -137 | -136 | N/A |
12/31/2019 | 339 | -235 | -152 | -151 | N/A |
9/30/2019 | 300 | -248 | -162 | -161 | N/A |
6/30/2019 | 264 | -268 | -186 | -184 | N/A |
3/31/2019 | 238 | -276 | -189 | -186 | N/A |
12/31/2018 | 224 | -245 | -170 | -167 | N/A |
9/30/2018 | 208 | -249 | -160 | -158 | N/A |
6/30/2018 | 185 | -252 | N/A | -174 | N/A |
3/31/2018 | 158 | -256 | N/A | -192 | N/A |
12/31/2017 | 125 | -289 | N/A | -218 | N/A |
9/30/2017 | 93 | -299 | N/A | -251 | N/A |
6/30/2017 | 63 | -306 | N/A | -242 | N/A |
3/31/2017 | 33 | -309 | N/A | -240 | N/A |
12/31/2016 | 17 | -271 | N/A | -208 | N/A |
9/30/2016 | 5 | -238 | N/A | -182 | N/A |
6/30/2016 | 0 | -206 | N/A | -165 | N/A |
3/31/2016 | 0 | -174 | N/A | -138 | N/A |
12/31/2015 | 0 | -164 | N/A | -122 | N/A |
9/30/2015 | 0 | -147 | N/A | -105 | N/A |
6/30/2015 | 0 | -133 | N/A | -91 | N/A |
3/31/2015 | 0 | -115 | N/A | -78 | N/A |
12/31/2014 | 0 | -92 | N/A | -66 | N/A |
9/30/2014 | 0 | -76 | N/A | -59 | N/A |
6/30/2014 | 0 | -62 | N/A | -51 | N/A |
3/31/2014 | 1 | -50 | N/A | -39 | N/A |
12/31/2013 | 1 | -38 | N/A | -32 | N/A |
애널리스트 미래 성장 예측
수입 대 저축률: ACAD 의 연간 예상 수익 증가율( 26.6% )이 saving rate( 2.6% 보다 높습니다. ).
수익 vs 시장: ACAD 의 연간 수익( 26.6% ) US 시장( 15.3% 보다 빠르게 성장할 것으로 예상됩니다. 15.3% 연간).
고성장 수익: ACAD 의 수입은 향후 3년 동안 상당히 증가할 것으로 예상됩니다.
수익 대 시장: ACAD 의 수익(연간 9.1% ) US 시장( 8.9% 보다 빠르게 성장할 것으로 예상됩니다. 8.9% 연간).
고성장 수익: ACAD 의 수익(연간 9.1% )은 연간 20% 보다 느리게 증가할 것으로 예상됩니다.
주당 순이익 성장 예측
미래 자기자본 수익률
미래 ROE: ACAD 의 자본 수익률은 3년 내에 최저 수준이 될 것으로 예상됩니다( 19.5 %).